CASE REPORT
A 75-year-old white man presented in September of 2004 to the urology service with a 2-month history of a rapidly enlarging mass of the glans penis that would occasionally bleed when traumatized. The patient denied any symptoms of urinary outflow obstruction. Physical examination was notable for an 0.8 ϫ 0.8-cm pedunculated mass of the glans penis with underlying pigmentation in a macular pattern extending onto the prepuce with a similar, separate, smaller area adjacent to the meatus. There was no palpable inguinal lymphadenopathy. Abdominal examination was negative for hepatosplenomegaly.
On the clinical impression that this mass was a pyogenic granuloma, excisional biopsy of the mass and a circumcision were performed. Histology was notable for an incompletely excised, 5-mm-thick, superficial spreading melanoma in the vertical growth phase, with a horizontal superficial component in the skin surrounding the lesion, prompting a referral to plastic surgery. A chest radiograph and computed tomographic scans of the head, chest, and abdomen were obtained and were negative for metastatic disease.
Refusing either a partial or a total penectomy, the patient underwent wide local excision of the macular area of pigmentation of the glans with split-thickness skin grafting and an incisional biopsy of the smaller pigmented area adjacent to the meatus. Histologic examination of these specimens was notable for superficial spreading melanoma. As there were two distinct separate lesions on the penis with an intervening skip area, involvement was multifocal in distribution. Figure 1 shows a lateral view of the glans penis after the initial biopsy before excision of the largest macular area of pigmentation of the glans. Note the smaller area of pigmentation adjacent to the meatus. Figure 2 is a frontal view of the penis. Figure 3 is a photomicrograph of a low-power view (5ϫ) of the main tumor mass. Figure 4 depicts a section of the mass at higher magnification (40ϫ) to show cellular detail. Figure 5 shows a section of the tumor (40ϫ) with a strongly positive stain for HMB-45. Figure 6 is a section of foreskin showing in situ disease (20ϫ), which was elsewhere focally invasive, adjacent to the main tumor mass. Note the pagetoid spread of malignant cells throughout the entire thickness of the epidermis.
DISCUSSION
Since the original report of malignant melanoma of the penis in 1859 by Murchinson, 10 a number of series of melanoma of both the penis and male urethra have been published. 1, 6, 8, 10 The penis is an uncommon site for melanoma.
6,10 A total of 0.16 percent, or four cases, in a review of 2418 cases of melanoma in one series 10 were noted to occur in the penis, constituting less than 1 percent of all malignancies of that site. Melanomas are noted to occur most frequently on the glans (55 percent) and on the prepuce (22 percent), shaft (9 percent), and urethral meatus (8 percent) in descending order. 10 Involvement of the urethra occurs most frequently in the fossa navicularis and less frequently in the pendulous, bulbous, and prostatic areas. 5 Melanoma of the urethra is less common than that of the penis. 1 On review of the literature, Manivel and Fraley determined that penile melanomas were more common than their urethral counterparts by a ratio of 2.4:1.
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Melanoma of the penis and urethra has a peak incidence in the 50-to 70-year-old age group, which is several decades older than the peak incidence of cutaneous melanomas elsewhere (i.e., 40 to 49 years of age). 6 However, there is a case report of an in situ melanoma on the frenulum of the penis in a 13-year-old boy. 1 It is most common in Caucasians, less common in Asians, and relatively rare in those of African descent. 5, 8 Delay in presentation is common and may be attributable to reluctance of the patient to seek medical attention because of denial or fear of the possible malignant nature of the lesion, initial misdiagnosis as either an infectious or inflammatory condition, or failure of the patient to note a clinically significant change in a long-standing lesion of the penis. 1 Patients with melanoma of the penis may present with either a long-standing lesion that undergoes enlargement or ulceration or the de novo appearance of a new pigmented lesion that pro- 1 Patients with melanoma of the urethra may present with one or more of the symptoms of a penile or urethral mass, dysuria, hematuria, melanuria, obstructive symptoms or a split in the urinary stream, 1 foul-smelling urine, or fistula formation. 8 The differential diagnosis of melanoma of the penis includes melanosis, 8, [11] [12] [13] squamous cell carcinoma, benign lentigo, lentiginous nevi, hemangiomas, and fixed drug eruption. 2 Transitional or squamous cell carcinoma form the differential diagnosis of melanoma of the urethra, as these are the two most commonly occurring malignancies in this area. 1 The occurrence of amelanotic melanomas in this region may pose a diagnostic pitfall for the unwary urologist or pathologist.
14 Histologic subtypes of melanoma that have been reported to occur on the penis include the superficial spreading, nodular, 15 mucosal (or acral) lentiginous, 2, 16, 17 and desmoplastic varieties. 18 Mucosal lentiginous melanomas appear to have a more aggressive clinical course, which may be caused by a delay in presentation and diagnosis. Mucosal lentiginous melanoma is the principal histologic subtype of the urethra. 17 Little is known about the pathogenesis of melanoma of the penis. The presence of genetic markers for cutaneous melanoma elsewhere as described by Brick et al. have not been reported in cases of melanoma of the penis. In one series, a single patient with a positive family history of cutaneous melanoma developed a lesion from a compound nevus of the penis. 1 Several other cases arising from preexisting nevi have also been reported, 6, 19 as have two cases of melanoma in situ in which no precursor lesion was noted. 1, 3 Melanosis has been proposed as a possible precursor 11, 19 and has a similar clinical appearance. 12 Leicht et al. theorize that there may be a biologic continuum of pigmented lesions, with those demonstrating acanthosis, melanocytic hyperplasia, and the presence of large dendritic processes representing an "evolving acral lentiginous melanoma." 11 The report of three separate lesions of malignant melanoma from an area of melanosis of the glans and prepuce 20 is strongly supportive of melanosis as a risk factor for melanoma of the penis. Although the pathogenesis for melanoma of the urethra is unknown, the high incidence of multicentricity 1, 5, 14 implies the presence of a field affect of the urethral mucosa.
As is the case with cutaneous melanoma, the prognosis for melanoma of the penis and urethra is dependent on the thickness of the primary lesion, as described by Breslow, and the stage of the disease at the time of presentation. 21 A mean delay in diagnosis of 24.2 months is largely responsible for the poor prognosis of patients with penile and urethral melanoma, allowing ample time for progression to the vertical growth phase. 8 An average lesion thickness of 5.96 mm, noted in Oldbring and Mikulowski's series of patients with melanoma of the penis and urethra, was associated with a poor prognosis, regardless of the treatment used. 9 Regardless of the treatment administered, the prognosis for melanoma of the penis and urethra has been poor, with most patients dying within 3 years of diagnosis. 8 To date, only a small number of patients surviving in excess of 5 years have been reported. 
The American Joint Committee on Cancer staging protocol for melanoma is most widely accepted, using the tumor, node, metastasis (or TNM) classification to describe the extent of disease. In this system, T designates the thickness of the primary tumor; N designates the extent of regional metastatic disease, and M designates the extent of distant metastases. The presence of ulceration raises the stage in each T subgroup. 22 The tumor, node, metastasis classification system is grouped into five clinical stages on the basis of prognosis. Stage 0 designates in situ melanoma; stage I, local disease; stage II, more advanced local disease; stage III, regional, in-transit, and/or satellite metastases; and stage IV, distant metastases. Stage IV is subclassified on the basis of the presence or absence of elevated serum lactate dehydrogenase. 22 The patient presented in our article was assessed as having American Joint Committee on Cancer stage IIC (T4b M0 N0) melanoma of the penis.
The primary treatment of melanoma of the penis and urethra is surgical. The main area of controversy of treatment lies with the extent of surgery for localized disease (i.e., American Joint Committee on Cancer stage I or II). Recommendations have ranged from wide local excision 6, 7 to partial 4, 6, 23 or total penectomy with bilateral radical groin dissection. 8, 9 Bracken and Diokno recommended radical phallectomy and bilateral groin dissections for melanomas of the penis and urethra, arguing that inadequate treatment with localized disease resulted in therapeutic failures. 24 Proponents for more radical surgery quote the high incidence of local recurrence with more conservative procedures. 9, 24 Stillwell et al. recommend either a distal penectomy or a wide local excision with a 3-to 5-cm margin for lesions less than 1.5 mm thick and excision with bilateral superficial inguinal dissection for lesions greater than 1.5 mm thick, reserving deep inguinal dissection for those with positive nodes. 6 Pietrzak et al. recently published a series of 49 patients who underwent surgery for invasive penile carcinoma. In 39 of those patients, an organsparing procedure was used. The types of procedures described included both glans-preserving and glans-removing procedures. As 80 percent of penile tumors occur on the glans, prepuce, and coronal sulcus, many tumors of the penis are amenable to treatment by this approach. 25 Glans-preserving procedures comprised partial glansectomy with primary closure and partial glansectomy with skin grafting.
Glans-removing procedures involved glansectomy with partial-thickness graft reconstruction applied in a quilting fashion to form a neoglans or glansectomy and distal corporectomy with quilting of a partial-thickness skin graft to create a neoglans, combined with a penile lengthening procedure. Of those who have had a partial glansectomy, there was one recurrence. In the patients who had undergone a glans-removing procedure, none have had a recurrence to date. The long-term rate of recurrence is not known, as the mean follow-up of patients in this series was 16 months.
Cabanas in 1977 reported the results of a technique of sentinel node biopsy in which a lymph node located at the anteromedial aspect of the superficial epigastric vein, above, and medial to the epigastric-saphenous junction was excised. The location of this node was based on the results of 100 lymphangiograms performed via the dorsal lymphatics of the penis. A 5-year survival reported was 90 percent for those with a negative sentinel node biopsy results, 70 percent when the sentinel node biopsy alone was involved, 50 percent with involvement of the sentinel node with other inguinal nodes, and 20 percent with involvement of iliac nodes. 26 As a result of this study, he concluded that the status of the sentinel node was predictive of the status of the remainder of the lymph node basin. 26 Others using his technique 27, 28 were not able to duplicate his results. This was because Cabanas' technique did not involve lymphatic mapping from the locus of the primary lesion and thus the true sentinel node in their cases was not located.
Identification of the sentinel node requires lymphatic mapping. Preoperatively, the patient is injected with a radioactive tracer such as technetium-99m-labeled colloid particles of human serum albumin at several sites around the primary tumor site, either the night before surgery or 2 to 3 hours preoperatively. A scintillation camera is then used to determine the site of the sentinel node(s), which is indicated on the overlying skin with indelible ink.
In the operating room, the patient is injected with a dye such as 1% Lymphazurin blue in a similar manner. A gamma probe is used to determine the location of the sentinel node. A node is considered a sentinel node if it is blue or "hot" (i.e., has a 10-second count greater than 10 times that of the background). All sentinel nodes are considered removed when the count of the operative field falls to that near background levels. The combination of both dye and radioactive labels Plastic and Reconstructive Surgery • August 2006 has been shown to be superior to either method alone.
Indications for sentinel node biopsy are changing continuously. Although initially reserved for cases of melanoma of intermediate thickness (i.e., Ͼ1.0 or Ͻ4.0 mm in depth), without clinical evidence of metastatic disease, 29 indications for sentinel node biopsy outside of this range are now being accepted increasingly. Indications for sentinel node biopsy for melanomas less than or equal to 1 mm in depth include ulceration, regression, or Clark's level IV or V. 29 In addition, sentinel node biopsy is now being called for melanomas with a Breslow thickness of greater than 4 mm, as a negative result has been shown to correlate with an increased disease-free survival. 30 The practice of reserving lymph node dissections only for patients with positive sentinal nodes in the treatment of melanoma is rapidly gaining wide acceptance. 31 The use of step sectioning, immunohistochemistry staining, and reverse-transcriptase polymerase chain reaction in the detection of malignant cells in lymph nodes has greatly increased the sensitivity of this technique and reduced the incidence of false-negative results. 29 The American Joint Committee on Cancer staging system for melanoma has a separate classification for retrieved lymph nodes with micrometastases. 22 As drainage of the proximal urethra is to the external and iliac lymph nodes, 9 laparoscopic sentinal lymph node biopsy may be used in the future for the management of patients presenting with melanomas of this site. This technique is already being used in the staging of cervical cancer. 32 The laparoscopic approach to the pelvic lymph nodes has been associated with considerably less morbidity than the open approach and has been used for pelvic lymphadenectomy for treatment of metastatic melanoma. 33 Inguinal lymphadenectomy is indicated for regional metastases (i.e., American Joint Committee on Cancer stage III disease), both for staging and to avoid the complications of tumor fungation. For disseminated metastases (i.e., American Joint Committee on Cancer stage IV disease), penectomy 1 or node dissection 6 should only be performed as necessary to avoid local complications. The prognosis for those with advanced disease is poor because of the lack of effective systemic chemotherapy. Adjuvant therapy with either bacillus Calmette-Guérin 1 or endolymphatic injection of iodine-131 lipiodol has been attempted, but neither modality has proved successful in significantly altering the clinical course. 9 A high recurrence rate of melanoma of the urethra (i.e., 29.4 to 60 percent) has been observed after treatment with partial penectomy, dictating the need for radical extirpative treatment including total penectomy and en bloc urethrectomy. 5, 14 This is attributable to the high incidence of multifocal involvement. 1, 5, 14 In our patient, there were two distinct lesions of the glans penis, an infiltrating superficial spreading melanoma of the glans and an in situ superficial spreading melanoma adjacent to the meatus. Although a case of acral lentiginous melanoma of the glans with a concomitant melanoma of the urethra has been described, 5 multifocal involvement of the cutaneous surface of the penis has not been previously reported. Our patient had no family history of the disease and described the lesion as arising within a matter of months. The depth of invasion of his melanoma, however, is indicative of a long-standing lesion of years in duration. As his glans was notable for multiple discrete areas of hyperpigmentation, it is possible that his disease arose from preexisting areas of melanosis that progressed through a biological continuum as described by Leicht et al. 11 There has been considerable improvement in the surgical management of patients with melanoma of the penis with respect to patient morbidity. There has been an increasing emphasis on organ preservation, sentinel node biopsy to determine the status of the inguinal node basin, and the use of endoscopic techniques for pelvic lymphadenectomy. However, the management of melanoma of the urethra still requires more aggressive treatment than that of the penis because of the high incidence of multifocal disease to prevent local recurrence.
Because of the relatively small numbers of patients involved, multi-institutional cooperative studies are needed to make further inroads in the treatment of this disease. A search for genetic markers should be conducted to determine whether this subpopulation shares the same genetic markers as cutaneous melanoma elsewhere. Reports of melanoma of the penis and urethra should include the location, thickness, histologic subtype, presence of ulceration, and origin from a precursor lesion if present. A family history of cutaneous melanoma, if present, should be noted. The importance of early recognition, early and appropriately aggressive surgical therapy, and the development of effective adjuvant therapy for the treatment of disseminated disease are of paramount importance in improving the prognosis of this disease.
Volume 118, Number 2 • Melanoma of the Penis 37e CONCLUSIONS Malignant melanomas of the penis and the male urethra are rare. Although little is known about its pathogenesis, preexisting nevi and possibly longstanding areas of melanosis may represent risk factors for development of penile melanoma. Patients as a rule present late, with a thick primary lesion and a high incidence of metastatic disease. As a result, there is often a delay in diagnosis and a poor clinical outcome for the vast majority of this patient population. Furthermore, there is a lack of consensus regarding the surgical treatment of this disease. Sentinel lymph node biopsy to determine the presence of regional metastatic disease is rapidly gaining acceptance in the management of this disease. We report the first known case of penile melanoma with multifocal involvement of the cutaneous surface of the glans penis and a review of the literature regarding the pathogenesis and treatment of melanoma of the penis and urethra. Multi-institutional collaborative studies should be undertaken to identify risk factors to enable earlier recognition and treatment.
